This website uses cookies to enhance the user experience.
BIOBANK AS

BIOBANK AS987 709 324

Research
Limited company
Holsetgata 22 2317 HAMAR, Norge
Services
/ Research
/ 72.110 Research and experimental development on biotechnology

BIOBANK AS

BioBank AS – Lagring for fremtida!

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Links

Organization

CEO
LB

Laila Bekk1976

Chairman of the board
OE

Olav Eik-Nes1957

Years since formation
20 years
since Mar 29, 2005
Type
Limited company
VAT registered
Yes
Number of employees
9

Ownership

Number of shares and share classes
300
1 share class
Total number of shareholders
3
companies

Financials

Total operating income 2024
14,606,653
NOK
Annual total result 2024
686,564
NOK
Total equity 2024
10,914,198
NOK
Last update: May 28, 2025

Management

Management / administration

NameRoleShares
LB

Laila Bekk

1976

Managing Director/CEO-

Board

NameRoleShares
OE

Olav Eik-Nes

1957

Chairman-
OM

Odd Magne Rødseth

1960

Board Member-
KM

Kristin Malonæs

1970

Board Member-

Others

NameRoleShares
H
HAMARREVISJON AS
Auditor-
A
AIDER AS
Accountant-
Last update: Dec 31, 2024

Ownership

Company shareholders

NameShare classTotal number of sharesShare
A
AQUAGEN AS
Ordinary shares
100
33.33 %
G
GENO SA
Ordinary shares
100
33.33 %
N
NORSVIN SA
Ordinary shares
100
33.33 %

Shares owned by the BIOBANK AS

NameShare classTotal number of sharesShare
S
SCANDIGEN LAB AS
Ordinary shares
250,000
50 %
Last update: Jun 2, 2025

Financials

in NOK

Summary

Year2024202320222021
Total operating income
14,606,653
13,930,391
14,537,421
13,311,240
Annual Total Result
686,564
1,507,067
299,550
732,771
Total assets
16,377,959
14,910,851
14,478,560
14,901,341
Total liabilities
5,463,762
4,683,218
5,757,993
6,480,324
Total equity
10,914,198
10,227,633
8,720,566
8,421,016

P&L

Year2024202320222021
Total operating income
14,606,653
13,930,391
14,537,421
13,311,240
Total operating costs
14,107,936
12,165,788
14,203,174
12,375,398
Operating result
498,717
1,764,603
334,247
935,842
Financial income/costs
381,630
167,217
37,104
-3,931
Profit before tax
880,347
1,931,820
371,351
931,911
Total tax & extraordinary income/cost
193,783
424,753
71,801
199,140
Annual Total Result
686,564
1,507,067
299,550
732,771

Balance overview

Year2024202320222021
Total fixed assets
1,786,111
1,860,139
2,396,482
2,720,840
Total current assets
14,591,848
13,050,712
12,082,078
12,180,501
Total assets
16,377,959
14,910,851
14,478,560
14,901,341
Short term debt
2,810,902
2,199,328
2,496,252
2,614,317
Long term debt
2,652,860
2,483,890
3,261,741
3,866,007
Total liabilities
5,463,762
4,683,218
5,757,993
6,480,324
Contributed capital
300,000
300,000
300,000
300,000
Retained earnings
10,614,198
9,927,633
8,420,566
8,121,016
Total equity
10,914,198
10,227,633
8,720,566
8,421,016
Total equity and liabilities
16,377,959
14,910,851
14,478,560
14,901,341

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology